MYB104 Antibody

What are MYB antibodies and what primary research applications are they used for?

MYB antibodies are immunological reagents designed to detect and study members of the MYB family of transcription factors, including B-MyB (MYBL2). These transcription factors play crucial roles in regulating cell survival, proliferation, and differentiation processes. MYB antibodies are primarily used in immunohistochemistry (IHC), Western blotting (WB), and immunoprecipitation (IP) applications to detect the presence, localization, and relative abundance of MYB proteins in biological samples . For example, Anti-B MyB antibody (ab114055) is a rabbit polyclonal antibody suitable for immunohistochemistry with paraffin-embedded samples, targeting a synthetic peptide within human MYBL2 amino acids 450-500 .

How do different MYB family antibodies compare in their specificity and applications?

Different MYB family antibodies vary significantly in their target specificity, host species, clonality, and validated applications:

• Rabbit polyclonal antibodies like Anti-B MyB (ab114055) target MYBL2 (B-Myb), which transactivates the expression of the CLU gene

• Mouse monoclonal antibodies such as Anti-Myb Antibody clone 1-1 target Myb/c-myb protein with different epitope recognition patterns

• Polyclonal antibodies typically offer broader epitope recognition

• Monoclonal antibodies provide higher specificity for a single epitope but may be more sensitive to epitope masking

The selection between these antibody types depends on the specific MYB family member being studied and the intended experimental applications.

What sample types and detection methods are typically validated for MYB antibodies?

MYB antibodies have been validated for various sample types and detection methods in research settings:

• Human samples: Anti-B MyB antibody (ab114055) is validated for use with human samples in immunohistochemistry with paraffin-embedded tissues (IHC-P)

• Mouse samples: Some MYB antibodies like Anti-Myb Antibody clone 1-1 have been validated for both human and mouse samples

• Detection methods: IHC-P, Western blotting (WB), and immunoprecipitation (IP) are commonly validated applications

• Specific protocols: Anti-B MyB antibody has been tested at 1/250 dilution for staining B MyB in formalin-fixed, paraffin-embedded human prostate carcinoma tissue using immunohistochemistry with DAB staining

What are the optimal conditions for using MYB antibodies in immunohistochemistry?

For optimal immunohistochemistry results with MYB antibodies, researchers should consider several key methodological factors:

• Sample Preparation: Formalin-fixed, paraffin-embedded tissues are commonly used. Proper fixation is critical - overfixation can mask epitopes while underfixation can compromise tissue morphology.

• Antigen Retrieval: Heat-induced epitope retrieval (HIER) is often necessary to unmask antigens after formalin fixation.

• Antibody Dilution: Based on validated protocols, Anti-B MyB antibody (ab114055) has been successfully used at 1/250 dilution for human prostate carcinoma tissue .

• Detection System: DAB (3,3'-diaminobenzidine) staining has been validated for visualizing MYB antibody binding in tissue sections, providing a brown precipitate at sites of antibody binding .

• Controls: Always include positive and negative controls. For B-MyB studies, prostate carcinoma tissue has been validated as an appropriate positive control .

• Incubation Conditions: Overnight incubation at 4°C often yields optimal results with lower background compared to shorter incubations at room temperature.

How can researchers optimize Western blot protocols for MYB protein detection?

Successful Western blotting for MYB proteins requires careful attention to these methodological considerations:

• Sample Preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • Ensure complete protein denaturation with SDS and reducing agents

  • Quantify protein concentration for equal loading

• Gel Selection and Transfer:

  • MYB proteins vary in size (B-MyB/MYBL2 is approximately 93-95 kDa)

  • 8-10% polyacrylamide gels are typically suitable

  • Semi-dry or wet transfer to PVDF membranes is recommended

• Blocking and Antibody Incubation:

  • 5% non-fat dry milk or BSA in TBST is commonly used for blocking

  • Anti-Myb antibodies like clone 1-1 should be diluted in fresh blocking buffer

  • Overnight incubation at 4°C often yields optimal results

• Detection Methods:

  • HRP-conjugated secondary antibodies with enhanced chemiluminescence

  • Consider fluorescent secondary antibodies for multiplex detection

• Controls and Normalization:

  • Loading controls (β-actin, GAPDH) for normalization

  • Positive controls from tissues/cells known to express MYB proteins

What controls should be included when using MYB antibodies in research?

Proper controls are essential for reliable and interpretable results when using MYB antibodies:

• Positive Controls:

  • Tissues/cells known to express the target MYB protein

  • For B-MyB/MYBL2, prostate carcinoma tissue has been validated

  • Recombinant protein or overexpression lysates can serve as definitive controls

• Negative Controls:

  • Primary antibody omission

  • Non-immune serum from the same species as the primary antibody

  • Tissues/cells known not to express the target protein

• Specificity Controls:

  • Blocking peptide competition to confirm antibody specificity

  • Use of multiple antibodies targeting different epitopes of the same protein

  • Knockdown/knockout validation where gene expression is reduced/eliminated

• Procedural Controls:

  • Isotype controls (especially for monoclonal antibodies like Anti-Myb Antibody clone 1-1)

  • Secondary antibody-only controls to assess non-specific binding

  • Processing controls subjected to identical procedures except antibody incubation

How can MYB antibodies be used for studying transcription factor dynamics?

MYB antibodies offer powerful tools for investigating transcription factor dynamics through several advanced techniques:

• Chromatin Immunoprecipitation (ChIP):

  • MYB antibodies can precipitate MYB proteins bound to DNA

  • Allows identification of MYB binding sites genome-wide

  • Can be coupled with sequencing (ChIP-seq) for comprehensive binding profiles

  • Critical for understanding transcriptional regulatory networks

• Co-Immunoprecipitation (Co-IP):

  • Identifies protein-protein interactions involving MYB factors

  • Helps elucidate transcriptional complexes and cofactors

  • Anti-Myb Antibody clone 1-1 has been validated for IP applications

• Cell Cycle Analysis:

  • MYB proteins like B-MyB/MYBL2 have cell cycle-dependent functions

  • Combined with cell synchronization and flow cytometry

  • Research has demonstrated cell cycle dependent oscillatory expression of transcription factors linked to RNA Polymerase II elongation and neoplastic transformation

What role do MYB antibodies play in cancer research?

MYB antibodies have proven valuable in cancer research through multiple applications:

• Diagnostic and Prognostic Markers:

  • Immunohistochemistry with MYB antibodies can assess expression in tumors

  • B-MyB/MYBL2 is involved in regulation of cell survival and proliferation

  • Anti-B MyB antibody has been used to study prostate carcinoma tissues

• Cancer Biology Mechanisms:

  • Research has shown that direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition (EMT) of breast cancer cells

  • MYB antibodies help track these changes in expression patterns

• Growth Regulation Studies:

  • Studies have documented an inhibitory role of Mir-29 in growth of breast cancer cells involving MYB pathways

  • c-Myb has been shown to inhibit myoblast fusion, highlighting its role in differentiation processes

• Therapeutic Target Validation:

  • Identifying MYB-dependent cancer subtypes

  • Evaluating potential of MYB inhibition as therapeutic strategy

  • Monitoring response to targeted therapies

How can MYB antibodies be integrated with emerging research technologies?

Integrating MYB antibodies with cutting-edge technologies creates powerful research approaches:

• Antibody Engineering Advances:

  • Recent research demonstrates that highly accurate antibody loop structure prediction enables effective zero-shot design of target-binding antibody loops

  • These advances could lead to improved MYB antibodies with enhanced specificity and sensitivity

• Therapeutic Antibody Development:

  • The safe profile of therapeutic antibodies demonstrated in clinical trials, such as the phase 1 study of m102.4 antibody, provides a model for developing research antibodies into therapeutic tools

  • In this study, single and repeated dosing showed linear pharmacokinetics with a median half-life ranging from 397-663 hours depending on dosage

• Multi-omics Integration:

  • Combining ChIP-seq using MYB antibodies with RNA-seq

  • Correlating MYB binding with gene expression changes

  • Integrating with proteomics and metabolomics data

• Advanced Imaging Applications:

  • Immunofluorescence with MYB antibodies in 3D cultures and tissue samples

  • Super-resolution microscopy for detailed localization studies

  • Live cell imaging when combined with fluorescent protein tags

How can researchers address non-specific binding when using MYB antibodies?

Non-specific binding is a common challenge with antibodies. Here are methodological approaches to address this issue:

• Optimization Strategies:

  • Titrate antibody concentration - test serial dilutions to find optimal signal-to-noise ratio

  • Modify blocking conditions - try different blocking agents (BSA, normal serum, commercial blockers)

  • Adjust incubation times and temperatures

  • Increase washing stringency with higher salt concentration or additional wash steps

• Sample-Specific Considerations:

  • Pre-adsorb antibody with tissues/cells lacking the target protein

  • Use tissue-specific blocking agents that contain potential cross-reactive proteins

  • Consider tissue autofluorescence or endogenous peroxidase activity for IHC applications

• Antibody Validation Approaches:

  • Peptide competition assays to confirm specificity

  • Use multiple antibodies targeting different epitopes

  • Compare with genetic models (knockdown/knockout) to confirm specificity

  • Consider monoclonal alternatives if using polyclonal antibodies

• Technical Modifications:

  • For IHC: optimize antigen retrieval methods for the specific MYB antibody being used

  • For Western blotting: use PVDF membranes which may provide better protein retention and sensitivity

What approaches can resolve inconsistent results with MYB antibodies?

Inconsistent results can undermine research progress. Here are methodological solutions:

• Standardization of Protocols:

  Parameter	Recommendation	Rationale
  Antibody Storage	Aliquot and store at -20°C or -80°C	Prevents freeze-thaw degradation
  Sample Preparation	Standardize lysis buffers and protocols	Ensures consistent protein extraction
  Incubation Conditions	Use temperature-controlled chambers	Reduces environment-related variability
  Detection Systems	Calibrate equipment regularly	Ensures consistent signal detection
  Reagent Quality	Use single lots when possible	Minimizes lot-to-lot variability

• Validation Strategies:

  • Confirm antibody performance with known positive controls such as prostate carcinoma tissue for B-MyB antibodies

  • Use multiple detection methods (e.g., IF, WB, IHC) to cross-validate findings

  • Consider antibody validation using knockout models or siRNA knockdown

• Technical Considerations:

  • For IHC: ensure consistent fixation times and processing methods

  • For IP: pre-clear lysates to reduce non-specific binding

  • Maintain detailed records of experimental parameters including antibody lot numbers

• Biological Variables:

  • Consider cell cycle dependency of MYB protein expression

  • Account for potential post-translational modifications affecting antibody binding

  • Examine sample heterogeneity and potential splice variants

How should researchers interpret contradictory findings from different MYB antibodies?

Contradictory findings from different antibodies require careful interpretation and resolution:

• Epitope Considerations:

  • Different antibodies recognize distinct epitopes that may be differentially accessible

  • The Anti-B MyB antibody (ab114055) targets an epitope within amino acids 450-500 , while other antibodies may target different regions

  • Post-translational modifications may affect epitope recognition

  • Protein conformation changes can mask or reveal epitopes

• Methodological Resolution Strategies:

  • Use multiple antibodies targeting different regions of the same protein

  • Compare monoclonal (like Anti-Myb clone 1-1) and polyclonal antibodies (like ab114055)

  • Validate with genetic approaches (overexpression, knockdown)

  • Perform epitope mapping to understand exactly what each antibody recognizes

• Reporting Recommendations:

  • Document all antibodies used (source, catalog number, lot)

  • Specify exact experimental conditions for each antibody

  • Transparently report discrepancies in findings

  • Discuss potential biological explanations for differences

What emerging techniques might enhance MYB antibody applications?

Several cutting-edge methodologies show promise for expanding MYB antibody applications:

• Advanced Antibody Engineering:

  • Recent breakthroughs in antibody loop structure prediction enable zero-shot design of target-binding antibody loops

  • This technology could lead to development of MYB antibodies with improved specificity and reduced cross-reactivity

  • Site-specific conjugation for improved functionality and detection sensitivity

• Advanced Imaging Technologies:

  • Super-resolution microscopy beyond diffraction limit for detailed localization studies

  • Light sheet microscopy for 3D tissue imaging of MYB expression patterns

  • Intravital microscopy for in vivo dynamics of MYB proteins

• Single-Cell and Spatial Proteomics:

  • Mass cytometry (CyTOF) with MYB antibodies for high-dimensional analysis

  • Imaging mass cytometry for spatial context of MYB expression

  • Single-cell Western blotting technologies for heterogeneity analysis

• Integration with AI and Machine Learning:

  • Automated image analysis for quantification of MYB expression in tissues

  • Pattern recognition in complex datasets involving MYB signaling pathways

  • Predictive modeling of MYB function in normal and disease states

How might MYB antibodies contribute to personalized medicine research?

MYB antibodies have significant potential in advancing personalized medicine:

• Biomarker Development:

  • MYB proteins as prognostic indicators in multiple cancers

  • Identification of patient subgroups with distinct MYB expression patterns

  • Monitoring treatment response through MYB target expression

• Therapeutic Target Validation:

  • Safety profiles established in clinical antibody trials provide models for therapeutic development

  • Phase 1 antibody trials have demonstrated good tolerability and predictable pharmacokinetics

  • Understanding of antibody half-life (ranging from 397-663 hours) informs dosing strategies

• Patient-Derived Models:

  • Characterizing MYB expression in patient-derived xenografts

  • Organoid cultures with MYB pathway analysis

  • Ex vivo drug sensitivity testing correlated with MYB status

• Combination Therapy Approaches:

  • Identifying synergistic targets in MYB-dependent cancers

  • Developing rational combination strategies

  • Overcoming resistance through pathway analysis

  • Monitoring pathway reactivation during treatment